Ensysce Biosciences, Inc. (ENSC): R&D Expense
$10.38M
Year ended 2025-12-31
$12.39M
Trailing 12 months to 2026-06-30
-19.4%
3-year compound annual growth
+18.8%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $10.38M | +43.7% | 2026-03-30, From 2025-01-01 |
| 2024-12-31 | $7.22M | -4.9% | 2026-03-30, From 2024-01-01 |
| 2023-12-31 | $7.59M | -61.7% | 2025-03-10, From 2023-01-01 |
| 2022-12-31 | $19.84M | +322.9% | 2024-03-15, From 2022-01-01 |
| 2021-12-31 | $4.69M | +6.8% | 2023-03-30, From 2021-01-01 |
| 2020-12-31 | $4.39M | n/a | 2022-03-31, From 2020-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Ensysce Biosciences, Inc. (ENSC) | 2025-12-31 | $10.38M | +43.7% |
| ProPhase Labs, Inc. (PRPH) | 2025-12-31 | $107.0K | -82.0% |
| China Pharma Holdings, Inc. (CPHI) | 2025-12-31 | $280.9K | -1.1% |
| Korro Bio, Inc. (KRRO) | 2025-12-31 | $65.58M | +3.0% |
| CervoMed Inc. (CRVO) | 2025-12-31 | $21.82M | +16.1% |
| Immunome Inc. (IMNM) | 2025-12-31 | $177.29M | +36.9% |
| Whitehawk Therapeutics, Inc. (WHWK) | 2025-12-31 | $90.96M | +78.3% |
| Marker Therapeutics, Inc. (MRKR) | 2025-12-31 | $11.80M | -12.4% |
| Ovid Therapeutics Inc. (OVID) | 2025-12-31 | $25.58M | -30.4% |
Compare ENSC, PRPH, CPHI, KRRO side by side · Screen every company in Pharmaceutical Preparations ↗